The treatment landscape of HER‐2 positive gastric cancer is undergoing a transformative phase, driven by the introduction of novel anti‐HER2 agents, combination therapies, and immunotherapy that show strong preclinical and clinical promise [61]. Here, ERBB2 is linked to gastric cancer.